These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 19715914

  • 1. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA, Rapamune Maintenance Regimen Study Group.
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [Abstract] [Full Text] [Related]

  • 2. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 3. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transpl Int; 2005 Jan 27; 18(1):22-8. PubMed ID: 15612979
    [Abstract] [Full Text] [Related]

  • 4. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 5. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C, Brault Y, Morales JM, Oberbauer R, Altieri P, Riad H, Mahony J, Messina M, Pussell B, Martínez JG, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Clin Transplant; 2007 Nov 15; 21(3):330-6. PubMed ID: 17488381
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 15; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 7. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J, Kahan BD.
    Transplant Proc; 2011 Dec 15; 43(10):3657-68. PubMed ID: 22172822
    [Abstract] [Full Text] [Related]

  • 8. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial.
    Oberbauer R, Hutchison B, Eris J, Arias M, Claesson K, Mota A, Kreis H, Kleinman L, Wang F, Chen J, Revicki DA, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Apr 27; 75(8):1277-85. PubMed ID: 12717216
    [Abstract] [Full Text] [Related]

  • 9. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G, Jamieson N, Oberbauer R, Arias M, Murgia MG, Blancho G, Sato R, Stoeckl M, Revicki DA.
    Transpl Int; 2007 Oct 27; 20(10):875-83. PubMed ID: 17854445
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF.
    J Am Soc Nephrol; 2006 Feb 27; 17(2):581-9. PubMed ID: 16434506
    [Abstract] [Full Text] [Related]

  • 11. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
    Friend P, Russ G, Oberbauer R, Murgia MG, Tufveson G, Chapman J, Blancho G, Mota A, Grandaliano G, Campistol JM, Brault Y, Burke JT, Rapamune Maintenance Regimen (RMR) Study Group.
    Transpl Int; 2007 Sep 27; 20(9):754-60. PubMed ID: 17565578
    [Abstract] [Full Text] [Related]

  • 12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 13. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
    van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L.
    Transplantation; 2003 Jun 27; 75(12):1934-9. PubMed ID: 12829890
    [Abstract] [Full Text] [Related]

  • 14. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Jun 27; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 15. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec 27; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 16. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
    Citterio F, Sparacino V, Altieri P, Rigotti P, Calabrese S, Poli M, Vinti V, Segoloni GP.
    Transplant Proc; 2005 Mar 27; 37(2):827-9. PubMed ID: 15848545
    [Abstract] [Full Text] [Related]

  • 17. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T, Kreis H, Friend P.
    Clin Transplant; 2004 Aug 27; 18(4):446-9. PubMed ID: 15233824
    [Abstract] [Full Text] [Related]

  • 18. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J.
    Transplantation; 2001 Sep 15; 72(5):777-86. PubMed ID: 11571437
    [Abstract] [Full Text] [Related]

  • 20. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y.
    Transplant Proc; 2009 Sep 15; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.